Genomics
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | 3.4m | 2.9m | 3.1m | 4.5m | 4.2m |
| % growth | 36 % | 370 % | 441 % | (15 %) | 6 % | 47 % | (6 %) |
| EBITDA | (3.8m) | (3.0m) | (8.0m) | (10.0m) | (16.6m) | (21.0m) | - |
| % EBITDA margin | (2871 %) | (479 %) | (236 %) | (346 %) | (545 %) | (468 %) | - |
| Profit | (4.0m) | (3.8m) | (3.0m) | (6.5m) | (12.8m) | (19.7m) | - |
| % profit margin | (2994 %) | (607 %) | (89 %) | (225 %) | (419 %) | (439 %) | - |
| R&D budget | 2.7m | 3.4m | 5.6m | 7.4m | 10.0m | 12.1m | - |
| R&D % of revenue | 2024 % | 541 % | 166 % | 256 % | 327 % | 270 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
| N/A | N/A | Seed | |
£10.3m | Series A | ||
£2.0m | Grant | ||
* | £25.0m | Series B | |
£8.0m | Series B | ||
$30.0m | Late VC | ||
* | £35.0m | Late VC | |
| Total Funding | €124m | ||
Recent News about Genomics
EditGenomics plc is an innovative health business dedicated to transforming health, healthcare, and drug discovery through the power of genomics. The company operates in the genomics market, providing solutions that empower patients, practitioners, pharmaceutical companies, healthcare providers, and payers to make genomically powered decisions for longer, healthier lives. Genomics plc's business model focuses on leveraging genomic data to drive transformational insights into human biology and disease, thereby improving the quality of healthcare delivery and drug discovery processes. The company generates revenue through partnerships with healthcare systems, pharmaceutical companies, and other stakeholders in the healthcare ecosystem. By integrating genomic data into clinical practice and research, Genomics plc aims to enhance personalized medicine and optimize treatment outcomes.
Keywords: genomics, healthcare, drug discovery, personalized medicine, genomic data, healthcare providers, pharmaceutical companies, patients, practitioners, insights.